Right Ventricular Failure in the ICU

The forgotten ventricle fights back

Critical Care · Seminar week 8 · released May 11, 2026 · includes a discussion video

RV failure kills differently than LV failure. Inhaled pulmonary vasodilators, mechanical support, and why your fluid strategy is probably wrong.

Learning Objectives

By the end of this seminar, participants will be able to:

1. Analyze the pathophysiology of RV failure in critical care settings, including the vicious cycle of RV pressure overload and ventricular interdependence
2. Perform shock differentiation using point-of-care ultrasound (POCUS), with emphasis on RV-specific sonographic findings
3. Develop hemodynamic management plans prioritizing vasopressors and volume status optimization in the RV failure patient
4. Identify risks associated with peri-intubation cardiovascular collapse in RV failure patients and apply mitigation strategies
5. Critically appraise the utility of mechanical circulatory support options for refractory RV failure

Section 1: RV Anatomy, Physiology, and the Pathophysiology of Failure

Duration: 15 min | Content Tier: MUST ACT

%%FIG0%% MUST ACT: The right ventricle is not simply a mirror image of the left ventricle — it is a fundamentally different chamber with different geometry, different muscle fiber architecture, and different responses to pressure and volume loading. Understanding these differences is essential to managing RV failure, because strategies that work for the LV often harm the RV.

Why the RV Is Different

The RV is a thin-walled, crescent-shaped chamber that wraps around the interventricular septum. In the normal state, the RV operates as a volume pump against a low-resistance pulmonary vascular bed, generating approximately one-sixth the stroke work of the LV. The RV wall thickness is only 3-5 mm, compared to 8-12 mm for the LV. This thin wall means the RV is exquisitely sensitive to acute increases in afterload — a 50% increase in pulmonary vascular resistance can reduce RV stroke volume by 30-40%.

Teaching Point: The RV tolerates volume overload relatively well but tolerates pressure overload very poorly. This is the fundamental principle that drives RV failure management: reduce afterload, optimize preload, and support contractility — in that order of priority.

The normal RV pressure-volume relationship is triangular, not rectangular like the LV. RV ejection continues even after peak pressure is reached, because the low pulmonary vascular impedance allows continued forward flow during pressure decline. This means the RV is heavily dependent on maintaining low pulmonary vascular resistance for effective ejection (PMID: 34605781).

The Vicious Cycle of RV Failure

%%FIG1%% MUST ACT: RV failure creates a self-perpetuating vicious cycle that, if not interrupted, leads rapidly to cardiogenic shock and death. The cycle proceeds as follows:

1. Increased RV afterload (from PE, ARDS, sepsis, or pulmonary hypertension) causes RV dilation
2. RV dilation shifts the interventricular septum leftward, compressing the LV cavity (ventricular interdependence)
3. LV compression reduces LV filling and cardiac output
4. Reduced cardiac output decreases coronary perfusion pressure
5. Reduced coronary perfusion causes RV ischemia (the RV is perfused primarily during systole, unlike the LV which is perfused during diastole)
6. RV ischemia worsens contractility, causing further dilation, and the cycle accelerates

Say Out Loud: "RV failure is a death spiral. Once the septum shifts left and coronary perfusion drops, you have minutes to hours to intervene before the patient is beyond rescue."

Nuance: The concept of ventricular interdependence is critically important. The interventricular septum contributes 20-40% of RV systolic function through its contraction. When the septum shifts leftward from RV dilation, this contribution is lost — and simultaneously, LV filling is impaired. This is why RV failure causes biventricular hemodynamic compromise, not just right-sided congestion (Evans L, et al., Surviving Sepsis Campaign, 2021; PMID: 34605781).

Common Causes of RV Failure in the ICU

Teaching Point: The causes of acute RV failure in the ICU can be categorized by the mechanism of injury:

Pressure overload (increased afterload):

• Massive or submassive pulmonary embolism
• Acute respiratory distress syndrome (ARDS) — RV failure occurs in 20-25% of moderate-severe ARDS
• Mechanical ventilation with excessive PEEP or driving pressure
• Pulmonary hypertension (acute-on-chronic or de novo)
• Left heart failure with secondary pulmonary hypertension

Volume overload:

• Aggressive fluid resuscitation in sepsis
• Tricuspid or pulmonary valve regurgitation
• Left-to-right intracardiac shunts

Contractile failure:

• RV myocardial infarction (typically from right coronary artery occlusion)
• Septic cardiomyopathy affecting the RV
• Post-cardiotomy RV dysfunction
• Myocarditis

Decision Point: The management approach differs fundamentally based on mechanism. Pressure overload requires afterload reduction. Volume overload requires volume removal. Contractile failure requires inotropic support. Misidentifying the mechanism — for example, giving aggressive fluids to a pressure-overloaded, dilated RV — can be rapidly fatal.

Audience Poll: What do you think is the most common cause of RV failure in ICU patients?

• A) Pulmonary embolism
• B) ARDS with high PEEP ventilation
• C) Sepsis with fluid overload
• D) RV myocardial infarction

Evidence:

• Delaney A, Borges-Sa M, Chew MS, et al. (2026). 'Current standard of care for septic shock.' Intensive care medicine. PMID: 41359028
• Evans L, Rhodes A, Alhazzani W, et al. (2021). 'Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.' Critical care medicine. PMID: 34605781

Section 2: POCUS in Shock Differentiation — The RV Assessment

Duration: 15 min | Content Tier: MUST ACT

%%FIG2%% MUST ACT: Point-of-care ultrasound is the single most important diagnostic tool for identifying RV failure at the bedside. Without POCUS, RV failure is frequently misdiagnosed as septic or distributive shock, leading to harmful management decisions — specifically, aggressive fluid resuscitation that further dilates an already failing RV.

The Focused RV Assessment

The focused POCUS assessment for RV failure can be completed in under 5 minutes and provides critical diagnostic and management information. The protocol follows a systematic approach:

1. Subcostal Four-Chamber View — RV:LV Ratio

Teaching Point: The single most important measurement is the RV:LV end-diastolic area ratio. Normally, the RV is smaller than the LV (ratio <0.6). In RV dilation:

• Ratio 0.6-1.0: Moderate RV dilation — the RV is approaching LV size
• Ratio >1.0: Severe RV dilation — the RV is larger than the LV, and ventricular interdependence is occurring
• Ratio >1.5: Critical RV dilation — expect hemodynamic compromise

Say Out Loud: "If the RV is bigger than the LV on subcostal view, this patient has RV failure until proven otherwise. Stop the fluids and start thinking about afterload reduction."

2. Apical Four-Chamber View — Septal Motion and TAPSE

The apical four-chamber view provides two critical pieces of information:

• Septal bowing: A leftward-bowing interventricular septum during systole indicates RV pressure overload. A "D-shaped" LV on short-axis view confirms this finding. This is a sign that RV afterload reduction is urgently needed.

• TAPSE (Tricuspid Annular Plane Systolic Excursion): Place the M-mode cursor through the lateral tricuspid annulus. TAPSE measures the longitudinal shortening of the RV free wall. Normal is >17 mm. Values <17 mm indicate RV systolic dysfunction. Values <10 mm indicate severe RV failure (Demi et al., 2023; PMID: 35993596).

3. Parasternal Short-Axis View — The "D-Sign"

Teaching Point: In the parasternal short-axis view at the papillary muscle level, the normal LV is circular. In RV pressure overload, the interventricular septum flattens during systole, creating a "D-shaped" LV. In RV volume overload, the septum flattens during diastole. In combined pressure and volume overload, the septum is flattened throughout the cardiac cycle. This distinction guides management.

4. IVC Assessment — Volume Status

The IVC diameter and respiratory variation provide guidance on volume status:

• Collapsed IVC (<1 cm) with >50% variation: Volume-responsive — consider cautious fluid challenge
• Dilated IVC (>2.1 cm) with <50% variation: Volume-overloaded — diuresis or ultrafiltration needed
• Moderately dilated IVC with minimal variation in a patient with RV failure: The RV is already overfilled — further fluids will worsen the situation

Nuance: In the mechanically ventilated patient, IVC assessment is more complex. Positive pressure ventilation reverses the normal respiratory variation. In these patients, a dilated IVC with minimal variation is common even with adequate volume status. Integrate the IVC findings with the overall clinical picture — RV size, septal position, TAPSE, and clinical indicators of perfusion.

5. Lung Ultrasound — The B-Line Assessment

Teaching Point: Lung ultrasound provides real-time assessment of pulmonary congestion. Bilateral B-lines (>3 per intercostal space in >2 zones bilaterally) indicate pulmonary edema. In the context of RV failure, bilateral B-lines suggest that the RV dysfunction is either secondary to left heart failure or that the patient has been over-resuscitated with fluids. This finding should prompt aggressive decongestion rather than further fluid administration.

POCUS Shock Differentiation Framework

Decision Point: The critical question at the bedside is: "What type of shock does this patient have?" POCUS provides the answer:

Audience Poll: How frequently do you use POCUS in practice for shock diagnosis?

• A) Every patient in shock gets POCUS within 15 minutes
• B) Most patients — when I remember or have time
• C) Occasionally — usually only when told to
• D) Rarely or never

Evidence:

• Demi L, Wolfram F, Klersy C, et al. (2023). 'New International Guidelines and Consensus on the Use of Lung Ultrasound.' Journal of ultrasound in medicine. PMID: 35993596

Section 3: Vasopressor and Inotrope Management in RV Failure

Duration: 15 min | Content Tier: MUST ACT

%%FIG3%% MUST ACT: Vasopressor and inotrope selection in RV failure is not a simple "pick one and titrate" exercise. The wrong agent — or the wrong dose of the right agent — can precipitate cardiovascular collapse. The hemodynamic goals in RV failure are fundamentally different from those in LV failure or distributive shock.

The Three Hemodynamic Goals

Framework:

1. Maintain coronary perfusion pressure — The RV is perfused during systole (unlike the LV, which is perfused during diastole). RV coronary perfusion pressure = mean arterial pressure minus RV systolic pressure. If MAP drops or RV systolic pressure rises, the RV becomes ischemic.

1. Reduce RV afterload — Lowering pulmonary vascular resistance reduces the work the failing RV must perform against. This is the most effective intervention for improving RV output.

1. Support RV contractility — Once preload and afterload are optimized, inotropic support augments RV stroke volume.

Vasopressor Selection

Teaching Point: The ideal vasopressor in RV failure increases systemic vascular resistance (to maintain MAP and coronary perfusion) without increasing pulmonary vascular resistance (which would worsen RV afterload). This pharmacologic profile narrows the options considerably.

Norepinephrine — First-Line Agent

Norepinephrine is the recommended first-line vasopressor in RV failure with shock. It primarily acts on alpha-1 receptors in the systemic vasculature, increasing SVR and MAP. It has modest beta-1 activity, providing mild inotropic support. Critically, at doses <0.5 mcg/kg/min, norepinephrine has minimal effect on pulmonary vascular resistance (Delaney et al., 2026; PMID: 41359028).

Say Out Loud: "In RV failure, norepinephrine is my first-line vasopressor. It raises MAP to perfuse the RV coronary circulation without significantly increasing pulmonary vascular resistance."

Vasopressin — The Ideal Second Agent

Vasopressin acts on V1 receptors in the systemic vasculature and V2 receptors in the renal collecting duct. It increases SVR without affecting pulmonary vascular resistance — and in some studies, it actually decreases PVR through V1-receptor-mediated release of nitric oxide in the pulmonary vasculature. This makes vasopressin uniquely suited as an adjunct in RV failure (Sacha & Bauer, 2023; PMID: 37479058).

The VASST trial demonstrated that early vasopressin initiation (at lower norepinephrine-equivalent doses) is associated with lower mortality compared to delayed initiation. Observational studies suggest that vasopressin initiation at norepinephrine doses <0.2 mcg/kg/min or lactate <4 mmol/L is associated with improved outcomes (PMID: 37479058).

Nuance: The optimal timing of vasopressin initiation remains debated. The Surviving Sepsis Campaign 2021 guidelines suggest adding vasopressin to norepinephrine to target MAP of 65 mmHg rather than escalating norepinephrine dose (PMID: 34605781). In RV failure specifically, early vasopressin initiation is particularly attractive because it avoids the potential adverse pulmonary vascular effects of high-dose norepinephrine.

Phenylephrine — Use with Extreme Caution

Decision Point: Phenylephrine is a pure alpha-1 agonist that increases SVR. However, it also increases pulmonary vascular resistance, making it potentially harmful in RV failure. Phenylephrine should only be used in RV failure when the primary concern is systemic vasodilation (e.g., post-induction hypotension during intubation) and only as a bridge to norepinephrine.

Inotrope Selection

Dobutamine — The First-Line Inotrope

When the RV requires inotropic support (contractile failure or inadequate response to afterload reduction), dobutamine is the first-line agent. It acts on beta-1 receptors to increase contractility and on beta-2 receptors to cause mild pulmonary vasodilation — a desirable combination in RV failure. Starting dose: 2.5-5 mcg/kg/min, titrated to effect.

Milrinone — The Pulmonary Vasodilator Inotrope

Milrinone, a phosphodiesterase-3 inhibitor, provides inotropic support and pulmonary vasodilation. This dual mechanism is theoretically ideal for RV failure. However, milrinone also causes systemic vasodilation, which can worsen hypotension and reduce RV coronary perfusion. It should be used cautiously and typically in combination with a vasopressor.

Teaching Point: The inotrope-vasopressor combination for severe RV failure with shock is typically: norepinephrine + vasopressin (to maintain MAP and coronary perfusion) + dobutamine or milrinone (for inotropy and pulmonary vasodilation). This triple-drug approach targets all three hemodynamic goals simultaneously.

Pulmonary Vasodilators

Nuance: Inhaled pulmonary vasodilators — nitric oxide (iNO) and epoprostenol — selectively reduce pulmonary vascular resistance without systemic vasodilation. They are ventilated-lung-selective, meaning they dilate vessels in ventilated lung units, improving V/Q matching. In refractory RV failure with elevated pulmonary pressures, inhaled pulmonary vasodilators can be life-saving.

• Inhaled nitric oxide (iNO): 20-40 ppm. Onset within minutes. Evidence strongest in post-cardiac surgery RV failure and persistent pulmonary hypertension.
• Inhaled epoprostenol: 10,000-50,000 ng/mL via inline nebulizer. Less expensive than iNO with comparable efficacy. Requires dedicated nursing protocols.

Audience Poll: Which vasopressor would you prioritize in RV failure with shock?

• A) Norepinephrine alone
• B) Norepinephrine + vasopressin
• C) Norepinephrine + dobutamine
• D) Phenylephrine

Evidence:

• Sacha GL, Bauer SR. (2023). 'Optimizing Vasopressin Use and Initiation Timing in Septic Shock.' Chest. PMID: 37479058
• Delaney A, et al. (2026). 'Current standard of care for septic shock.' Intensive care medicine. PMID: 41359028
• Evans L, et al. (2021). 'Surviving Sepsis Campaign.' Critical care medicine. PMID: 34605781

Section 4: Volume Management — The Preload Paradox

Duration: 10 min | Content Tier: Nuance

Nuance: Volume management in RV failure is one of the most challenging and controversial areas in critical care. The textbook teaching of "the failing RV needs preload" is dangerously oversimplified. The reality is nuanced: some patients need volume, most need volume removal, and getting it wrong in either direction can be fatal.

The Starling Curve of the Failing RV

The normal RV operates on the ascending limb of the Frank-Starling curve — increased preload leads to increased stroke volume. But the failing, dilated RV has moved to the flat or descending portion of the curve. At this point, additional volume does not increase stroke volume — instead, it further dilates the RV, worsens septal shift, impairs LV filling, and reduces cardiac output.

Teaching Point: The key clinical question is: "Is this RV operating on the ascending or flat portion of the Starling curve?" POCUS provides the answer:

• Small, underfilled RV + collapsed IVC: The RV is on the ascending limb. A cautious fluid challenge (250 mL over 10-15 minutes with reassessment) is appropriate.
• Dilated RV + plethoric IVC: The RV is on the flat/descending limb. Further fluids will cause harm. Initiate diuresis or ultrafiltration.

Say Out Loud: "Before giving fluids to any shocked patient, I ask myself: what does the RV look like? If the RV is already dilated and the IVC is plethoric, more fluid is the enemy."

Diuresis vs. Ultrafiltration

Decision Point: When volume removal is indicated, the choice between diuretics and ultrafiltration depends on the clinical scenario:

Loop diuretics (furosemide):

• First-line for volume removal in most cases
• High-dose IV furosemide (bolus or continuous infusion) is preferred over low-dose oral dosing
• Target urine output: 1-3 mL/kg/hr in the acute setting
• Monitor serum electrolytes (K+, Mg2+) and renal function closely
• Consider adding thiazide diuretic (metolazone) for diuretic resistance ("sequential nephron blockade")

Continuous renal replacement therapy / ultrafiltration:

• Indicated when diuretics fail (diuretic resistance)
• Provides precise, predictable volume removal
• Allows simultaneous correction of electrolyte abnormalities
• Better hemodynamic tolerance than intermittent hemodialysis
• Use net ultrafiltration rates of 1-2 mL/kg/hr to avoid hemodynamic instability

Nuance: The 2021 Surviving Sepsis Campaign guidelines recommend against excessive fluid resuscitation and advocate for early reassessment of volume status using dynamic indices (PMID: 34605781). In the context of RV failure, this recommendation is especially important — the threshold for harm from excess volume is much lower than in patients with normal RV function.

Audience Poll: In cases of RV failure, do you prefer ultrafiltration over diuretics?

• A) Always — more precise and predictable
• B) Only when diuretics fail
• C) I rarely use ultrafiltration
• D) I'm not sure when to choose one over the other

Section 5: Peri-Intubation Strategies in RV Failure

Duration: 12 min | Content Tier: Teaching Point

%%FIG4%% Teaching Point: Intubation is one of the most dangerous moments for a patient with RV failure. The combination of induction agents (which reduce SVR and preload), positive pressure ventilation (which increases RV afterload), and the physiologic stress of laryngoscopy can precipitate cardiovascular collapse. Up to 25% of patients with RV failure experience peri-intubation cardiac arrest.

Why Intubation Is Dangerous in RV Failure

The mechanisms of peri-intubation hemodynamic collapse in RV failure are predictable:

1. Induction agents reduce SVR and preload: Propofol, etomidate, and ketamine all reduce systemic vascular resistance to varying degrees. In a patient whose cardiac output is already marginal, even modest reductions in preload or afterload can be catastrophic.

1. Positive pressure ventilation increases RV afterload: Spontaneous breathing generates negative intrathoracic pressure, which aids RV filling and reduces RV afterload. Positive pressure ventilation reverses both effects — it impairs venous return (reducing preload) and increases transpulmonary pressure (increasing afterload). The transition from spontaneous breathing to positive pressure ventilation is the most dangerous hemodynamic moment (Peled et al., 2024; PMID: 39115488).

1. Hypoxia and hypercarbia during intubation worsen pulmonary vasoconstriction: Any period of desaturation during intubation causes acute pulmonary vasoconstriction, dramatically increasing RV afterload at the worst possible time.

1. Apnea eliminates the respiratory pump: During the apneic period, loss of respiratory cycling eliminates the respiratory pump contribution to venous return, reducing RV preload.

The RV-Safe Intubation Protocol

MUST ACT: Every intubation of an RV failure patient should follow a structured approach designed to minimize hemodynamic compromise:

Framework: The PREPARE Protocol for RV Intubation

P — Pre-optimize hemodynamics

• Start vasopressor infusion BEFORE induction (norepinephrine or vasopressin)
• Prepare push-dose vasopressors: phenylephrine 100 mcg/mL syringes or epinephrine 10 mcg/mL syringes at bedside
• If not already on vasopressors, consider starting norepinephrine at 0.05 mcg/kg/min before induction

R — Reduce afterload where possible

• If on inhaled pulmonary vasodilators (iNO, epoprostenol), ensure they continue through the intubation circuit
• Have inhaled NO ready to start immediately post-intubation if not already in use

E — Ensure oxygenation

• Maximize preoxygenation: 5 minutes of high-flow nasal cannula (HFNC) at 60 L/min with FiO2 1.0
• Apneic oxygenation via nasal cannula during laryngoscopy
• Target SpO2 >95% before induction — any desaturation will cause acute pulmonary vasoconstriction

P — Pick the right induction agent

• Ketamine (1-2 mg/kg IV) is preferred — it maintains sympathetic tone, supporting SVR and heart rate
• Etomidate (0.3 mg/kg IV) is an alternative — hemodynamically neutral but does not provide sympathetic stimulation
• Avoid propofol — significant SVR reduction can be catastrophic

A — Adjust ventilator settings immediately

• Low tidal volume (6 mL/kg IBW)
• Low PEEP initially (5 cmH2O, titrate carefully)
• Avoid plateau pressures >27 cmH2O
• Target permissive hypercapnia only if hemodynamically tolerated — hypercarbia causes pulmonary vasoconstriction

R — Reassess with POCUS post-intubation

• Immediately assess RV size, septal position, and IVC after initiation of positive pressure ventilation
• Compare to pre-intubation findings — if RV dilation has acutely worsened, reduce PEEP and tidal volume

E — Escalate vasopressors proactively

• Expect hemodynamic deterioration and treat it preemptively rather than reactively
• Have a low threshold for vasopressor boluses during the first 15 minutes post-intubation

Say Out Loud: "I never intubate an RV failure patient without vasopressors running, push-dose pressors at the bedside, and ketamine as my induction agent. The airway is important, but the hemodynamics will kill them first."

Audience Poll: Have you encountered any complications during intubation in patients with RV failure?

• A) Yes — peri-intubation cardiac arrest
• B) Yes — severe hypotension requiring vasopressor escalation
• C) Yes — desaturation but recovered
• D) No major complications
• E) I haven't intubated a patient with known RV failure

Evidence:

• Peled Y, Ducharme A, Kittleson M, et al. (2024). 'ISHLT Guidelines for the Evaluation and Care of Cardiac Transplant Candidates.' Journal of heart and lung transplantation. PMID: 39115488

Section 6: Mechanical Circulatory Support for Refractory RV Failure

Duration: 12 min | Content Tier: Nuance

%%FIG5%% Nuance: When medical management fails — when vasopressors, inotropes, pulmonary vasodilators, and optimal ventilator management are insufficient to maintain adequate organ perfusion — mechanical circulatory support (MCS) becomes the rescue therapy. The decision to initiate MCS in RV failure is one of the most consequential in critical care medicine, and timing is critical: too late, and multi-organ failure is irreversible; too early, and the patient may have responded to continued medical optimization.

Indications for MCS in RV Failure

Decision Point: Consider MCS when the following criteria are met despite maximal medical therapy:

• Cardiac index <2.0 L/min/m2 despite multi-agent vasopressor and inotrope support
• Central venous pressure rising with declining cardiac output (reflecting ongoing RV dilation)
• End-organ dysfunction — rising lactate, oliguria, hepatic congestion, altered mental status
• Escalating vasopressor requirements without hemodynamic improvement
• Peri-intubation or post-intubation hemodynamic collapse unresponsive to medical management

MCS Options for RV Failure

1. Veno-Arterial ECMO (VA-ECMO)

VA-ECMO provides complete cardiopulmonary support by draining deoxygenated blood from the right atrium and returning oxygenated blood to the arterial system (typically via the femoral artery). In the context of RV failure:

• Advantages: Complete biventricular support, oxygenation, CO2 removal, rapid deployment
• Disadvantages: Does not directly unload the RV (blood is returned to the arterial system, increasing LV afterload), requires anticoagulation, limb ischemia risk, differential hypoxemia with upper-body desaturation (Harlequin syndrome)
• Bridge strategy: VA-ECMO can serve as a bridge to recovery (if the cause of RV failure is reversible, such as massive PE or post-cardiotomy), bridge to decision, or bridge to transplant/durable VAD

2. Right Ventricular Assist Devices (RVAD)

Temporary RVADs directly unload the RV by draining blood from the right atrium and delivering it to the pulmonary artery, effectively bypassing the failing RV. Options include:

• Impella RP: Percutaneously placed via the femoral vein, positioned across the tricuspid and pulmonic valves. Provides up to 4 L/min of flow. FDA-approved for RV failure post-LVAD implantation or post-cardiotomy. Emerging evidence supports use in other causes of RV failure.
• Protek Duo: A dual-lumen cannula placed via the right internal jugular vein, with the drainage lumen in the right atrium and the return lumen in the pulmonary artery. Can be combined with an oxygenator for Oxy-RVAD support. Advantage: single-site cannulation.
• Surgical RVAD: Centrally cannulated, typically RA to PA circuit with centrifugal pump. Most commonly used post-cardiotomy. Requires surgical implantation.

3. Veno-Venous ECMO (VV-ECMO)

VV-ECMO does not provide direct hemodynamic support but can be beneficial in RV failure secondary to severe ARDS:

• By providing gas exchange, VV-ECMO allows reduction in ventilator support (lower PEEP, lower driving pressure)
• Reduced ventilator-induced RV afterload allows RV recovery
• Does not directly unload the RV or augment cardiac output

Teaching Point: The choice of MCS platform depends on the cause of RV failure, the degree of hemodynamic compromise, and the institutional expertise available:

Nuance: The timing of MCS initiation is perhaps more important than the choice of device. Retrospective data consistently show that outcomes are worse when MCS is initiated as a "rescue" after prolonged refractory shock compared to earlier, more proactive deployment. The concept of "shock teams" — multidisciplinary teams that rapidly assess MCS candidacy — is emerging as a best practice (Peled et al., 2024; PMID: 39115488).

Say Out Loud: "If I'm on my third vasopressor and the lactate is still rising, I need to be on the phone with the MCS team now — not in two hours when the patient has arrested."

Audience Poll: How often have you used ECMO in RV failure management?

• A) Regularly — our unit has a robust ECMO program
• B) Occasionally — a few times in my career
• C) Never — but I've considered it
• D) Never — our institution doesn't have ECMO capability

Evidence:

• Peled Y, Ducharme A, Kittleson M, et al. (2024). 'ISHLT Guidelines for the Evaluation and Care of Cardiac Transplant Candidates.' Journal of heart and lung transplantation. PMID: 39115488

Clinical Cases

Case 1: The Septic Patient with Occult RV Failure

Presentation: A 62-year-old man with a history of COPD and recent community-acquired pneumonia presents to the ICU with septic shock. HR 118, BP 78/42, MAP 54, lactate 5.8 mmol/L, SpO2 89% on 6L nasal cannula. He has received 30 mL/kg crystalloid in the ED with minimal hemodynamic improvement. JVP is elevated to 14 cm. The ED team has started norepinephrine at 0.1 mcg/kg/min.

Audience Poll: What is your next step?

• A) Give another 500 mL crystalloid bolus
• B) Increase norepinephrine to 0.2 mcg/kg/min
• C) Perform bedside POCUS
• D) Start dobutamine

The POCUS: Bedside echo reveals a dilated RV with RV:LV ratio of 1.3. TAPSE is 12 mm (severely reduced). The interventricular septum bows toward the LV during systole. IVC is 2.4 cm with <10% respiratory variation. Lung ultrasound shows bilateral B-lines in dependent zones.

Decision Point: This patient has RV failure with volume overload, NOT fluid-responsive septic shock. Despite having "sepsis," additional fluids will worsen the situation by further dilating the RV and worsening ventricular interdependence.

Management:

1. Stop further fluids — the IVC is plethoric and the RV is already dilated
2. Add vasopressin at 0.03 units/min — to augment SVR without increasing PVR
3. Start dobutamine at 2.5 mcg/kg/min — the TAPSE of 12 mm indicates RV contractile failure
4. Initiate IV furosemide 40 mg bolus then 10 mg/hr infusion — the bilateral B-lines and plethoric IVC indicate volume overload
5. Start antibiotics — source control remains paramount
6. Avoid intubation if possible — use HFNC at 60 L/min, FiO2 1.0

Outcome: Over the next 6 hours, the patient's MAP improves to 68 on norepinephrine 0.08 + vasopressin 0.03 + dobutamine 5. Net fluid balance is -1.5L via furosemide. Repeat POCUS shows improvement in RV:LV ratio to 0.9 and TAPSE to 14 mm. The COPD exacerbation and pneumonia had caused acute pulmonary hypertension, leading to RV failure — not typical fluid-responsive septic shock.

Key Teaching Point: This case illustrates the danger of applying the "30 mL/kg crystalloid" sepsis bundle reflexively without assessing the RV. POCUS within the first 15 minutes would have identified the RV failure and prevented harmful fluid administration (PMID: 41359028, 37479058).

Case 2: Post-PE RV Failure and the Intubation Crisis

Presentation: A 48-year-old woman presents with acute dyspnea and syncope. CT angiogram reveals bilateral saddle pulmonary emboli. HR 130, BP 88/52, SpO2 91% on 15L non-rebreather. Troponin elevated. BNP 1,850 pg/mL. The patient is anxious, diaphoretic, and using accessory muscles.

The Deterioration: The respiratory therapist calls: "She's getting tired, SpO2 dropping to 85%. We need to intubate."

Decision Point: This patient has massive PE with RV failure. Intubation in this setting carries a 25% risk of peri-intubation cardiac arrest. Before proceeding, the team must prepare meticulously.

The RV-Safe Intubation:

1. Pre-optimization: Norepinephrine started at 0.1 mcg/kg/min. Push-dose epinephrine (10 mcg/mL) syringes prepared. HFNC at 60 L/min for preoxygenation.
2. Induction: Ketamine 1.5 mg/kg IV (to maintain sympathetic tone). Rocuronium 1.2 mg/kg for RSI.
3. Post-intubation: Immediate low tidal volume (6 mL/kg), PEEP 5, FiO2 1.0. Norepinephrine bolus of 20 mcg given during induction for transient hypotension.

The Crisis: Despite preparation, BP drops to 60/30 immediately post-intubation. The team reduces PEEP to 3, gives push-dose epinephrine 20 mcg IV, and increases norepinephrine. BP stabilizes at 82/48.

Definitive Management: Systemic thrombolysis with alteplase 100 mg IV over 2 hours. Over the next 4 hours, RV function improves, vasopressors are weaned, and repeat echo shows improving RV:LV ratio.

Key Teaching Point: This case demonstrates the PREPARE protocol in action. Without pre-optimization with vasopressors and push-dose pressors at the bedside, this patient would likely have arrested during intubation. The choice of ketamine over propofol was life-saving (PMID: 39115488).

Case 3: The ARDS Patient with Ventilator-Induced RV Failure

Presentation: A 55-year-old woman with pneumonia-related ARDS is on day 3 of mechanical ventilation. Current settings: Vt 6 mL/kg, PEEP 14, FiO2 0.8, RR 28. P/F ratio 85. She has been hemodynamically stable on low-dose norepinephrine. Over the past 2 hours, her MAP has dropped from 72 to 58 despite increasing norepinephrine to 0.15 mcg/kg/min. CVP has risen from 10 to 18. Lactate has increased from 1.8 to 4.2.

The POCUS Pivot: Bedside echo reveals a newly dilated RV with RV:LV ratio 1.4. TAPSE has dropped from 18 mm (measured yesterday) to 11 mm. D-shaped LV on short-axis view. The culprit: PEEP of 14 cmH2O is causing excessive RV afterload.

Nuance: In ARDS, there is an inherent tension between lung-protective ventilation (which requires adequate PEEP to prevent atelectasis and atelectrauma) and RV protection (which requires lower PEEP and driving pressure to avoid RV afterload increase). This balance is one of the most challenging aspects of ARDS management.

Management:

1. Reduce PEEP from 14 to 8 cmH2O — accepting modest desaturation to protect the RV
2. Prone positioning — improves oxygenation through improved V/Q matching, allowing PEEP reduction. Also unloads the RV by reducing transpulmonary pressure
3. Start inhaled epoprostenol via inline nebulizer — selective pulmonary vasodilation to reduce PVR
4. Add vasopressin 0.03 units/min — SVR support without PVR increase
5. Consider VV-ECMO if oxygenation cannot be maintained with RV-protective ventilator settings

Outcome: PEEP reduction to 8 and prone positioning improve SpO2 to 93% on FiO2 0.6. Inhaled epoprostenol further improves oxygenation. Repeat POCUS after 4 hours shows RV:LV ratio improving to 0.9 and TAPSE 15 mm. Lactate normalizes over 12 hours.

Key Teaching Point: Ventilator-induced RV failure is one of the most under-recognized causes of hemodynamic deterioration in ARDS. When a previously stable ARDS patient develops new hypotension with rising CVP, perform POCUS immediately — the ventilator may be killing the RV.

Case 4: Refractory RV Failure and the MCS Decision

Presentation: A 42-year-old man with idiopathic pulmonary arterial hypertension presents with decompensated RV failure. Despite medical therapy (norepinephrine 0.3 mcg/kg/min, vasopressin 0.04 units/min, dobutamine 10 mcg/kg/min, inhaled nitric oxide 40 ppm), he remains in cardiogenic shock: CI 1.6 L/min/m2, CVP 24, MAP 56, lactate 7.2, anuric.

Decision Point: This patient has exhausted medical management. Multi-organ failure is imminent. The critical questions:

1. Is the cause of RV failure reversible? In idiopathic PAH with a first presentation of decompensation, recovery is unlikely without advanced therapies. MCS is a bridge to transplant evaluation, not a bridge to recovery.

1. Is the patient a transplant candidate? If yes, MCS provides the time needed for evaluation and organ allocation. If no, the goals of care discussion must happen now.

1. Which MCS platform? For isolated RV failure with adequate gas exchange, a percutaneous RVAD (Impella RP or Protek Duo) provides targeted RV support. If biventricular failure or gas exchange failure develops, VA-ECMO is needed.

Management: After multidisciplinary discussion with cardiology, cardiac surgery, and palliative care, the team proceeds with Protek Duo placement via right internal jugular vein. Flow is established at 4.5 L/min. Within 2 hours: CVP decreases to 14, MAP rises to 72, lactate begins trending down. The patient is referred for transplant evaluation.

Key Teaching Point: The MCS decision in RV failure is not just a technical question — it is an ethical and goals-of-care question. MCS without a viable exit strategy (recovery, transplant, or durable device) is not appropriate. The "shock team" model facilitates rapid, multidisciplinary decision-making in these high-stakes situations (PMID: 39115488).

Case 5: RV Failure in Sepsis — The Volume Dilemma

Presentation: A 70-year-old woman with type 2 diabetes and chronic kidney disease presents with perforated diverticulitis and septic shock. After source control surgery, she is in the SICU on norepinephrine 0.2 mcg/kg/min. The surgical team requests "more fluids" because the CVP is only 8 and the urine output is 15 mL/hr.

Teaching Point: CVP alone is a poor predictor of volume responsiveness. In the presence of RV failure, a "low" CVP of 8 does not necessarily mean the patient needs more volume — it may reflect the RV's inability to generate higher filling pressures despite being adequately or over-filled.

The POCUS Assessment: RV:LV ratio is 1.1. TAPSE is 14 mm. IVC is 2.0 cm with 15% variation. The septum is flattened. The RV is dilated, not under-filled.

Management:

1. Hold further fluids — the RV is dilated despite the "low" CVP
2. Add vasopressin — to augment MAP and support coronary perfusion
3. Accept a lower urine output target — oliguria in this context reflects RV failure and venous congestion, not hypovolemia
4. Start low-dose dobutamine — to support RV contractility given the reduced TAPSE
5. Monitor with serial POCUS — repeat assessments every 4-6 hours to guide therapy

Outcome: Over 48 hours, the sepsis resolves with antibiotics and source control. The RV function gradually improves. Vasopressors are weaned. Urine output recovers to >0.5 mL/kg/hr.

Key Teaching Point: The CVP is not a volume target — it is a reflection of the interaction between venous return and cardiac function. In RV failure, managing to a CVP target will lead to harmful over-resuscitation. Use POCUS, not CVP, to guide volume decisions (PMID: 41359028, 34605781).

Tonight on Shift

When you walk into the ICU tonight, remember these six things:

1. The RV is not a small LV — it is thin-walled, crescent-shaped, and exquisitely sensitive to afterload. A 50% increase in PVR can drop RV output by 30-40%. Think about the RV differently from the LV, because the management is different.

1. POCUS before fluids, always — assess RV size (RV:LV ratio), function (TAPSE), septal position, and IVC before giving a single bolus. A dilated RV with a plethoric IVC does not need more fluid — it needs diuresis and afterload reduction.

1. Norepinephrine + vasopressin is the vasopressor foundation — norepinephrine maintains coronary perfusion without significantly increasing PVR. Vasopressin may actually decrease PVR. Together, they address the hemodynamic goals of RV failure.

1. Intubation is a high-risk procedure in RV failure — use the PREPARE protocol: pre-optimize with vasopressors, preoxygenate with HFNC, choose ketamine, have push-dose pressors at the bedside, and start low PEEP post-intubation.

1. When the ventilator is killing the RV, fix the ventilator — if a previously stable ARDS patient develops new hypotension with rising CVP, check POCUS for new RV dilation. Consider PEEP reduction, prone positioning, and inhaled pulmonary vasodilators.

1. Call the MCS team early, not late — if you are on your third vasopressor with a rising lactate, the MCS discussion should be happening now. Outcomes are consistently better with earlier MCS deployment than with "rescue" initiation after prolonged shock.

References

1. Delaney A, Borges-Sa M, Chew MS, et al. Current standard of care for septic shock. Intensive care medicine. 2026;52(1):15-31. PMID: 41359028.
2. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Critical care medicine. 2021;49(11):e1063-e1143. PMID: 34605781.
3. Demi L, Wolfram F, Klersy C, et al. New International Guidelines and Consensus on the Use of Lung Ultrasound. Journal of ultrasound in medicine. 2023;42(2):309-344. PMID: 35993596.
4. Sacha GL, Bauer SR. Optimizing Vasopressin Use and Initiation Timing in Septic Shock: A Narrative Review. Chest. 2023;164(5):1127-1135. PMID: 37479058.
5. Peled Y, Ducharme A, Kittleson M, et al. International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates — 2024. Journal of heart and lung transplantation. 2024;43(10):e545-e690. PMID: 39115488.
6. Weiss SL, Peters MJ, Alhazzani W, et al. Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children. Pediatric critical care medicine. 2020;21(2):e52-e106. PMID: 32032273.
7. Vogelmeier CF, et al. Goals of COPD treatment: Focus on symptoms and exacerbations. Respiratory medicine. 2020;166:105938. PMID: 32250871.
8. Garcia-Tsao G, Abraldes JG, Rich NE, et al. AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review. Gastroenterology. 2024;166(1):67-79. PMID: 37978969.

Read this seminar as Markdown · All seminars · Lecture library · Question bank